Nephros Appoints Daron Evans to Board of Directors

              Nephros Appoints Daron Evans to Board of Directors

PR Newswire

RIVER EDGE, N.J., Nov. 29, 2013

RIVER EDGE, N.J., Nov.29, 2013 /PRNewswire/ --Nephros, Inc. (OTC Bulletin
Board: NEPH), a commercial stage medical device company that develops and
sells high performance liquid purification ultrafilters, announced today the
appointment of Daron Evans to its Board of Directors. Mr. Evans replaces James
S. Scibetta who will be leaving the Board effective December 31, 2013. Mr.
Evans was also named a member of the Audit Committee.

Mr. Evans is a life sciences executive with over 20 years of financial
leadership and operational experience. Mr. Evans is currently a Partner at The
Highland Group, an operational consulting practice that partners with
industrial clients to deliver targeted results, and a Director on the Board of
Zumbro Discovery, an early stage company developing a novel therapy for
resistant hypertension. Mr. Evans was most recently Chief Financial Officer
of Nile Therapeutics, Inc., from 2007 until its merger with Capricor, Inc. in
November 2013. From 2006 to 2007, he was Director of Business Assessment for
Vistakon, a division of Johnson & Johnson Corp. From 2004 to 2006, he was
Associate Director of Portfolio Mgmt & Business Analytics at Scios, Inc. after
its acquisition by Johnson & Johnson Corp. Mr. Evans was a co-founder of
Applied Neuronal Network Dynamics, Inc. and served as its President from 2002
to 2004. From 1995 to 2002, Mr. Evans served in various roles at consulting
firms Arthur D. Little and Booz Allen & Hamilton. Mr. Evans is the author of
four U.S. patents. Mr. Evans received his Bachelor of Science in Chemical
Engineering from Rice University, his Master of Science in Biomedical
Engineering from a joint program at the University of Texas at Arlington and
Southwestern Medical School and his MBA from the Fuqua School of Business at
Duke University.

"I am very pleased to welcome Daron to Nephros' Board of Directors," stated
John C. Houghton, CEO of Nephros. "Daron's extensive operational and business
development experience will be a welcome complement to the Board."

"I am very impressed with the Nephros team and the wide range of commercial
opportunities for the company's products," stated Mr. Evans. "I look forward
to being an active member of the Board as Nephros seeks to capitalize on these

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells
high performance liquid purification filters. Our filters, which we call
ultrafilters, are primarily used in dialysis centers and healthcare facilities
for the production of ultrapure water and bicarbonate.

We were founded in 1997 by healthcare professionals affiliated with Columbia
University Medical Center/New York-Presbyterian Hospital to develop and
commercialize an alternative method to hemodialysis (HD). In 2009, we began to
extend our filtration technologies to meet the demand for liquid purification
in other areas, in particular water purification.

Presently, we offer seven types of ultrafilters for sale to customers in four

  oDialysis Centers – Water/Bicarbonate: Treatment of both water and
    bicarbonate for the production of ultrapure dialysate
  oHospitals and Other Healthcare Facilities: As part of a multi-barrier
    approach to help minimize exposure to waterborne contaminants
  oMilitary: Highly compact, individual water purification devices used by
    soldiers to produce safe drinking water in the field
  oDialysis Centers – Blood: Clearance of toxins from blood using an
    alternative method to HD in patients with chronic renal failure

For more information about Nephros, please visit the company's website at

Forward-Looking Statements

This press release contains certain "forward-looking statements." Such
statements include statements that are not historical facts, including
statements which may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. Forward-looking
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond our control. Actual results may differ
materially from the expectations contained in the forward looking statements.

Factors that may cause such differences include, but are not limited to, the
risks that:

  owe may not be able to continue as a going concern;
  othe voluntary recalls of point of use (POU) and DSU in-line ultrafilters
    used in hospital water treatment applications and the related
    circumstances could subject us to claims or proceedings which may
    adversely impact our sales and revenues;
  owe face significant challenges in obtaining market acceptance of our
    products, which could adversely affect our potential sales and revenues;
  othere are product-related deaths or serious injuries or product
    malfunctions, which could trigger recalls, class action lawsuits and other
    events that could cause us to incur expenses and may also limit our
    ability to generate revenues from such products;
  owe face potential liability associated with the production, marketing and
    sale of our products, and/or the expense of defending against claims of
    product liability, could materially deplete our assets and generate
    negative publicity which could impair our reputation;
  oto the extent our products or marketing materials are found to violate any
    provisions of the FDC Act or any other statutes or regulations, then we
    could be subject to enforcement actions by the FDA or other governmental
  owe may not be able to obtain funding if and when needed or on terms
    favorable to us in order to continue operations;
  owe may not have sufficient capital to successfully implement our business
  owe may not be able to effectively market our products;
  owe may not be able to sell our water filtration products or chronic renal
    failure therapy products at competitive prices or profitably;
  owe may encounter problems with our suppliers, manufacturers and
  owe may encounter unanticipated internal control deficiencies or weaknesses
    or ineffective disclosure controls and procedures;
  owe may not obtain appropriate or necessary regulatory approvals to achieve
    our business plan;
  oproducts that appeared promising to us in research or clinical trials may
    not demonstrate anticipated efficacy, safety or cost savings in subsequent
    preclinical or clinical trials;
  owe may not be able to secure or enforce adequate legal protection,
    including patent protection, for our products; and
  owe may not be able to achieve sales growth in key geographic markets.

More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth in our filings
with the SEC, including our Annual Report on Form 10-K for the fiscal year
ended December 31, 2012 and our other periodic reports filed with the SEC. We
urge you to read those documents free of charge at the SEC's web site at do not undertake to publicly update or revise our
forward-looking statements as a result of new information, future events or
otherwise, except as required by law.

SOURCE Nephros, Inc.

Contact: Eileen Sukumaran, 201.343.5202
Press spacebar to pause and continue. Press esc to stop.